Navigation Links
Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Date:11/4/2010

nd return of rights under the collaboration, including to APD597, we look forward to pursuing additional opportunities in this area."

Upon termination of the collaboration, all rights under licenses granted by Arena to Ortho-McNeil-Janssen under the agreement will terminate and revert to Arena, including rights relating to APD597. Ortho-McNeil-Janssen will also be required to deliver and assign to Arena rights and information relating to regulatory filings, including the Investigational New Drug Application (IND) relating to APD597, as well as certain other technology that may be useful to the development of GPR119 agonists that were subject to the collaboration. In addition, Ortho-McNeil-Janssen will cease reimbursing Arena for the cost of prosecuting Arena's GPR119 patent portfolio.

Arena owns a broad array of internally discovered, oral GPR119 agonists, including next generation compounds that Arena discovered after the research portion of its collaboration with Ortho-McNeil-Janssen ended in October 2007, and a portfolio of patent applications and, in some cases, granted patents directed to a range of materials and methods that are related to the discovery and development of GPR119 receptor agonists. Arena believes that approximately half of the top 20 pharmaceutical companies in the world have either acknowledged having an internal or collaborative GPR119 program or published medicinal chemistry patents directed to GPR119 agonists. The technologies covered by Arena's patents and patent applications include materials and methods that may be used to identify and determine the activity of molecules that modulate the GPR119 receptor, methods that measure the incretin response to GPR119 agonists and pharmaceutical compositions containing GPR119 agonists along with DPP-4 inhibitors.

About GPR119Arena believes GPR119 represents a novel pharmaceutical mechanism for discovering oral small molecule agonists for the treatment of diabetes. GPR
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
2. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
3. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
4. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... According to a new market ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and Orthopedic ... Trends and Forecast, 2014 - 2020", the global surgical ... in 2013 and is expected to grow at a ... an estimated value of USD 295.5 million in 2020. ...
(Date:7/29/2014)... 2014 Numotion,s Board of Directors has announced that ... be the company,s new Chief Executive Officer. ... GE where he worked primarily for GE Healthcare Services, running ... $5 billion. His most recent position was as President and ... am thrilled to join Numotion," said Mike Swinford . ...
(Date:7/29/2014)... 29, 2014 McGraw-Hill Education Professional, a leading ... technical, and medical communities, has announced the launch of ... application of the world-renowned medical education platform. ... App , available for download onto all iOS and ... to gain access to valuable AccessMedicine diagnostic ...
Breaking Medicine Technology:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3
... GARDEN CITY, New York, Oct. 7 ... Merkin recognize and congratulate seniors enrolled with HCP, IPA ... concern, health care reform, directly to members of Congress, ... http://www.newscom.com/cgi-bin/prnh/20091007/LA89266 ) , Dr. John Gastright, Senior ...
... , WALTHAM, Mass., Oct. 7 Nova Biomedical Corporation, ... that the company,s independent, wholly owned subsidiary, Sanvita CBGM, ... Sanvita, Inc., a subsidiary of CCS Medical, Inc. ... through this transaction, Nova,s Consumer Blood Glucose Monitoring (CBGM) ...
Cached Medicine Technology:HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC 2HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC 3Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medical's Subsidiary, Sanvita, Inc. 2
(Date:7/29/2014)... HealthDay Reporter TUESDAY, July ... on a task, various brain connections fire up. But ... with autism, according to a small new study. ... even less of this "brain flexibility," the researchers found. ... when children with autism are faced with new situations," ...
(Date:7/29/2014)... The Board of Governors of the State Bar ... Connie Akridge to serve as a trustee of ... the Foundation. Akridge served as President of the State Bar ... Holland & Hart in Las Vegas, providing tailored counsel on ... and healthcare clients for more than 25 years. She regularly ...
(Date:7/29/2014)... 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. , The study finds that the ...
(Date:7/29/2014)... The Law Offices of Michael Cordova is proud to ... organization providing grief camps for kids, teens, adults, and families. ... clients experience from the death of a loved one. ... Stepping Stones of Hope, as they provide hope and healing ... also includes a monthly support group and a variety of ...
(Date:7/29/2014)... headache sufferers to record the severity and regularity of ... Griffith research study. , A new approach to the ... with their triggers and is being led by Professor ... Health program. , He has developed an approach designed ... their headaches called Learning to Cope with Triggers (LCT). ...
Breaking Medicine News(10 mins):Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2
... April 27 BioTrends is pleased to announce the ... SIMPONI (R) . Cenotcor ... for SIMPONI (R) (generic name: golimumab) ... anti-TNF-alpha therapy, SIMPONI is approved for the treatment of ...
... WASHINGTON, April 27 Speaker Nancy ... virus: "This afternoon, Majority Leader Hoyer and I were ... Obama Administration,s preparations to deal with the public health ... briefed us on the efforts that are being made ...
... 27 Speaker Nancy Pelosi released the following statement ... serve as Ambassador at Large and Global AIDS Coordinator:"President ... Ambassador at Large and Global AIDS Coordinator signals the ... Dr. Goosby is an excellent choice and is uniquely ...
... April 27 Young Innovations, Inc. (Nasdaq: YDNT ... 2009. Sales for the first quarter of 2009 were ... the $24.4 million reported in the first quarter of 2008. ... first quarter of 2009 from $4.6 million in the first ...
... BAX ), will host its annual shareholders meeting ... (10:30 a.m. Central Time)This call is being webcast by Thomson/CCBN ... http://www.baxter.com/ . The conference call ... It cannot be recorded or rebroadcast without Baxter,s permission.The webcast ...
... HSKA ) announces the following Webcast: (Logo: ... to Its Annual Meeting of Stockholders on the WebWhen: ... www.heska.com (click on the Annual Meeting of ... Live over the Internet -- Simply log on ...
Cached Medicine News:Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 3Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 4Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 5Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 6Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: